| Page 1627 | Kisaco Research
 

Henrik Bjørn Nielsen

CSO
Clinical Microbiomics

Henrik Bjørn Nielsen

CSO
Clinical Microbiomics

Henrik Bjørn Nielsen

CSO
Clinical Microbiomics
 

Ruth Luna Ann

Assistant Professor
Baylor College of Medicine

Ruth Luna Ann

Assistant Professor
Baylor College of Medicine

Ruth Luna Ann

Assistant Professor
Baylor College of Medicine
 

Romaine Daillere

Co-Founder & Head of Preclinical Research
Everimmune

Romain Daillère completed his PhD in 2015 in the laboratory of Professor Laurence Zitvogel at the Gustave Roussy Cancer Campus (GRCC), Villejuif-Grand Paris/France. His research focuses on the complex interplay between gut microbiota and the efficacy of anticancer regimens. He previously graduated as a biotechnology engineer at the Ecole Supérieure de Biotechnology de Strasbourg (Trinational School of Strasbourg), and worked at the Ragon Institute of MIT, MGH and Harvard in Boston. Co-founder of EverImmune. Co-Inventor of EverImmune Technology.

Read full bio

Romaine Daillere

Co-Founder & Head of Preclinical Research
Everimmune

Romaine Daillere

Co-Founder & Head of Preclinical Research
Everimmune

Romain Daillère completed his PhD in 2015 in the laboratory of Professor Laurence Zitvogel at the Gustave Roussy Cancer Campus (GRCC), Villejuif-Grand Paris/France. His research focuses on the complex interplay between gut microbiota and the efficacy of anticancer regimens. He previously graduated as a biotechnology engineer at the Ecole Supérieure de Biotechnology de Strasbourg (Trinational School of Strasbourg), and worked at the Ragon Institute of MIT, MGH and Harvard in Boston. Co-founder of EverImmune. Co-Inventor of EverImmune Technology. He currently acts as head of the preclinical research of EverImmune.

 

Rochellys Diaz Heijtz

Associate Professor
Karolinska Institute

Rochellys Diaz Heijtz

Associate Professor
Karolinska Institute

Rochellys Diaz Heijtz

Associate Professor
Karolinska Institute
 

John Weinberg

Chief Medical Officer
MaaT Pharma

John Weinberg

Chief Medical Officer
MaaT Pharma

John Weinberg

Chief Medical Officer
MaaT Pharma
 

Denise Kelly

Consultant
Seventure

Denise Kelly

Consultant
Seventure

Denise Kelly

Consultant
Seventure
 

Anita Patel Jusnes

Chief Commercial Officer
Genetic Analysis

Anita Patel Jusnes

Chief Commercial Officer
Genetic Analysis

Anita Patel Jusnes

Chief Commercial Officer
Genetic Analysis
 

Aaron Anselmo

Assistant Professor
The University of North Carolina at Chapel Hill

Aaron Anselmo

Assistant Professor
The University of North Carolina at Chapel Hill

Aaron Anselmo

Assistant Professor
The University of North Carolina at Chapel Hill
 
Microbiome Connect: Skin EU 2021
7-9 Dec 2021
VIRTUAL EVENT
With key CPG brands launching skin microbiome focused brands over the last few years, skin microbiome is entering the mainstream of the beauty and personal care industry. The field is still in a nascent stage, but as next generation sequencing techniques and big data analysis improve, a galaxy of new information is set to be uncovered. With new regulation coming in to hold back the use of unsubstantiated claims, with high profile cases including Clariant, understanding the research and governing of this space has never been more important.Join us this December to find out about the latest R&D and regulation that is shaping the direction for skin microbiome product development with our expert speaker faculty of key industry representatives and academics."An amazing event, bringing you close to industrial representatives and providing you with the opportunity to not only understand what companies are doing but also to talk with them in engage in discussion. What a great networking opportunity" - KU Leuven
Visit Site
 

Shai Ufaz

CEO and Co-Founder
ViAqua Therapeutics

Shai Ufaz brings over 15 years of experience in biotechnology and molecular biology project management.  Prior to establishing ViAqua, Shai served as project manager at Protalix Biotherapeutics, a biotechnology pharmaceutical company and as Team leader at TransAlgae, an algae-based biotech startup. Shai holds a Ph.D. in plant biotechnology from Tel Aviv University and a postdoctoral fellow from the Weizmann Institute of Science.

Read full bio

Shai Ufaz

CEO and Co-Founder
ViAqua Therapeutics

Shai Ufaz

CEO and Co-Founder
ViAqua Therapeutics

Shai Ufaz brings over 15 years of experience in biotechnology and molecular biology project management.  Prior to establishing ViAqua, Shai served as project manager at Protalix Biotherapeutics, a biotechnology pharmaceutical company and as Team leader at TransAlgae, an algae-based biotech startup. Shai holds a Ph.D. in plant biotechnology from Tel Aviv University and a postdoctoral fellow from the Weizmann Institute of Science.